Cell therapy offers the potential to transform chronic diseases into curable conditions with a single treatment. However, high costs, long production cycles, and slow development have limited its accessibility.

Taiwan Bio is addressing these challenges with the FAST CGT platform, designed to reduce costs, enhance efficacy, shorten needle-to-needle time, and accelerate development. By optimizing design and lowering manufacturing expenses, we aim to make next-generation cell therapies more accessible, unlocking their full potential.